US Bancorp’s Codiak BioSciences, Inc. Common Stock CDAK Stock Holding History

US Bancorp’s Portfolio CDAK Stock Details CDAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-300	Closed	-$52	–	4208
2023 Q1	$52	Hold	300	–	–	﹤0.01%	4055
2022 Q4	$119	Hold	300	–	–	﹤0.01%	4089
2022 Q3	$0	Hold	300	–	–	﹤0.01%	4281
2022 Q2	$1K	Hold	300	–	–	﹤0.01%	4047
2022 Q1	$2K	Hold	300	–	–	﹤0.01%	3891
2021 Q4	$3K	Hold	300	–	–	﹤0.01%	3854
2021 Q3	$5K	Hold	300	–	–	﹤0.01%	3677
2021 Q2	$6K	Buy	+300	New	+$5.76K	﹤0.01%	3588

US Bancorp's CDAK Position: Q2 2023 in Review

US Bancorp sold out of Codiak BioSciences, Inc. Common Stock (CDAK) in Q2 2023, closing a stake of 300 shares — an estimated $52 sold.

US Bancorp first reported a position in CDAK in Q2 2021 and held it in 8 quarters. The position peaked at $6K in Q2 2021. 1 fund tracked by Wall St. Rank holds CDAK as of Q2 2023.

US Bancorp reported no remaining Codiak BioSciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
US Bancorp sold 300 Codiak BioSciences, Inc. Common Stock shares in Q2 2023, an estimated $52.
US Bancorp first reported a position in Codiak BioSciences, Inc. Common Stock in Q2 2021 and held it in 8 quarters.
US Bancorp's Codiak BioSciences, Inc. Common Stock position peaked at $6K in Q2 2021.
1 fund tracked by Wall St. Rank held Codiak BioSciences, Inc. Common Stock as of Q2 2023.

Based on US Bancorp's 13F filing for Q2 2023, filed 10 Aug 2023.